A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Non-small Cell Lung Cancer Clinical Trial

— UV1-hTERT2012L  

Official title:

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01789099
• Other study ID #: 2012-001852-20
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: April 8, 2013
• Est. completion date: April 2023

Study information

• Verified date: May 2021
• Source: Ultimovacs ASA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Study recruitment completed at 6 patients in every dose level.

The main study treatment phase of this study is completed and will be reported separately.

Follow-up is ongoing

Description:

This is an open label dose-escalating phase I/IIa study of UV1 peptide vaccination in patients with NSCLC after completion of radiation therapy and/or chemotherapy. Patients will be enrolled in this study if they have achieved complete response (CR), partial response (PR) or stable disease (SD) at least 4 weeks after completion of standard first line therapy.

The following 2-step design will be used:

1. Conventional dose escalation with at least 3 patients per dose level (3 selected dose levels).

2. Expansion of each dose level to a total of 6 patients for assessment of immune response levels.

13 UV1 vaccinations will be given during the first 6 months (week 26) of treatment, unless clinical deterioration or unacceptable toxicity is encountered. Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine ®) will be used as adjuvant for 11 of the 13 doses of UV1.

After completion of the main study treatment period at week 26, if the patient agrees, additional vaccinations may be considered for the following patients:

• Immune responders within first 6 months

• Immune non-responders providing they have at least SD

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: April 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with Non Small Cell Lung Cancer (NSCLC) who has been treated with palliative radiotherapy and/or at least three courses of chemotherapy, and has achieved stable disease (SD), partial response (PR) or complete response (CR) confirmed by CT scan at least 4 weeks after end of treatment. Previous curative radiotherapy is allowed as long as the patient has relapsed and received palliative chemotherapy.

• No evidence of disease progression at the time of inclusion

• Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

• Must be at least 18 years of age.

• Must have lab values as follows:

• White Blood Cells = 1.5 x 109/L

• Platelets = 100 x 109/L

• Hemoglobin = 9g/dL (= 5.6 mmol/L)

• Creatinine = 140 µmol/L

• Bilirubin < 20% above the upper limit of normal

• ASAT and ALAT = 2.5 the upper limit of normal

• Albumin = 2.5 g/L

• Signed informed consent

Exclusion Criteria:

• History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB or effectively treated malignancy that has been in remission for over 5 years and is highly likely to have been cured.

• Treatment with any other investigational medicinal product (IMP) within 4 weeks prior to first administration of study drug.

• Adverse reactions to vaccines such as anaphylaxis or other serious reactions.

• History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, sclerodermia, polymyositis-dermatomyositis, juvenile onset insulin-dependent diabetes, or a vasculitic syndrome.

• Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.

• Known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may however participate provided they meet the following criteria:

1. Inactive metastases (without evidence of progression which is documented by CT or MRI within 4 weeks prior to the planned study treatment date), and

2. If prednisolone or equivalent treatment is required; no more </=10mg/day is permitted.

• Active infection requiring antibiotic therapy.

• Pregnancy or lactation.

• Woman of childbearing potential not using any reliable and adequate contraceptive methods defined as use of oral, implanted, injectable, and mechanical or barrier products for the prevention of pregnancy.

• Known hypersensitivity to any of the components of the vaccine

• Known hypersensitivity to Leukine®, yeast derived products or any component of the product

• Patients who test positive for hepatitis B, C or HIV.

• Any other anti-tumor treatment within 4 weeks of study entry (including chemotherapy, immunotherapy, endocrine therapy, cytokines, interferons, protease inhibitors and gene therapy).

• Use of not permitted concomitant medication:

• chronic corticosteroids except for asthma inhalers / topical use

• any agent with a known effect on the immune system, unless it is being given at dose levels that are not immunosuppressive, e.g. prednisone at 10mg/day or less.

• any alternative and complementary drugs that may affect the immune system or be potentially harmful to patients participating in phase I studies.

• Any reason why, in the opinion of the investigator, the patient should not participate.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• UV1 synthetic peptide vaccine and GM-CSF

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (2)

Lead Sponsor	Collaborator
Ultimovacs ASA	Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Potential correlation between human cytomegalovirus status and immune response	Determination of human cytomegalovirus (CMV) status	Up to 2 years and 3 months
Other	Further characterization of the immune reaction triggered by the treatment.	Extended immunological analysis.	Up to 2 years and 3 months
Primary	Assessment of safety and tolerability of UV1.	Frequency and severity of adverse events and serious adverse events. Biochemistry and hematology results, vital signs and ECOG performance status will be assessed.	up to 2 years and 3 months.
Primary	Immunological response	Number of T-cell responses including time to T-cell responses (up to 6 months), level of response and duration of response.	Up to 2 years and 3 months.
Secondary	Assessment of anti tumor activity	Tumor response and progression free survival (PFS)	Up to 2 years and 3 months
Secondary	Selection of biological dose of peptides for further clinical trials.	Safety profile and immunological responses of each dose level.	Up to 2 years and 3 months